Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SAN DIEGO, May 08, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2017, before the opening of trading on Monday, May 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Monday, May 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2361 (preferred), or (888) 466-4462 (toll-free), and reference confirmation code 9047479. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9047479. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
